<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04827732</url>
  </required_header>
  <id_info>
    <org_study_id>202103218</org_study_id>
    <nct_id>NCT04827732</nct_id>
  </id_info>
  <brief_title>Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in Recurrent Rectal Cancer</brief_title>
  <acronym>IMPARC</acronym>
  <official_title>Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in the Reirradiation of Locoregionally Recurrent Rectal Cancer - IMPARC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine the maximum tolerated dose (MTD) of&#xD;
      hypofractionated IMPT for the reirradiation of locoregionally recurrent rectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of reirradiation using hypofractionated IMPT</measure>
    <time_frame>Through 6 months from start of treatment for all participants enrolled (estimated to be 42 months)</time_frame>
    <description>MTD is defined as the dose associated with a 35% probability of dose-limiting toxicity (DLT).&#xD;
DLT is defined as any toxicity listed below that occurs within 6 months from start of treatment and is considered possibly, probably, or definitely related to proton reirradiation:&#xD;
Any grade 5 toxicities&#xD;
Any grade 4-5 GI toxicities&#xD;
Bowel obstruction&#xD;
Grade 3-5: diarrhea; anal, colonic, or bowel ulcers; bladder perforation; any fistula formations; peripheral motor/sensory neuropathy of the pelvis above baseline; osteonecrosis/soft tissue necrosis; radiation dermatitis; hematuria; hematochezia; bowel/pelvic hemorrhage; reproductive tract toxicity&#xD;
Toxicity will be graded using CTCAE v5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical complete response rate</measure>
    <time_frame>Within 6-8 weeks post-completion of radiation therapy (estimated to be 7-9 weeks)</time_frame>
    <description>-DRE, endoscopy, and cross sectional imaging will be used to measure clinical complete response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median freedom from locoregional progression (FFLP)</measure>
    <time_frame>At 12 months post-radiation therapy (estimated to be 12 months and 1 week)</time_frame>
    <description>-Defined as time from end of radiation therapy to date of first local or regional tumor progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival (OS)</measure>
    <time_frame>At 12 months post-radiation therapy (estimated to be 12 months and 1 week)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median progression-free survival (PFS)</measure>
    <time_frame>At 12 months post-radiation therapy (estimated to be 12 months and 1 week)</time_frame>
    <description>-Defined as time from end of radiation therapy to the earliest date of locoregional progression, distant progression, or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life as measured by the EORTC QLQ-C30</measure>
    <time_frame>Prior to start of radiation therapy, 1-2 weeks post radiation therapy, 3 months post radiation therapy, 6 months post radiation therapy, 9 months post radiation therapy and 12 months post radiation therapy</time_frame>
    <description>-The EORTC QLQ-C30 consists of a 30-question questionnaire, which assesses patient well-being with five functional scales (the physical, role, emotional, cognitive, social, and global). It also includes three symptom scales (fatigue, pain, nausea/vomiting) and six single items (dyspnea, sleep disturbance, appetite loss, diarrhea, constipation, and financial impact). Single-item QL scores for overall physical condition (question 29), overall quality of life (question 30), and the global and social functioning scales have been shown to be prognostic for overall survival in adult patients with advanced malignancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life as measured by the EORTC QLQ-CR29</measure>
    <time_frame>Prior to start of radiation therapy, 1-2 weeks post radiation therapy, 3 months post radiation therapy, 6 months post radiation therapy, 9 months post radiation therapy and 12 months post radiation therapy</time_frame>
    <description>-The QLQ-CR29 contains 29 questions, including items in 4 scales (urinary frequency, blood/mucus in stools, stool frequency, body image) and 19 single items (urinary incontinence, dysuria, abdominal pain, buttock pain, bloating, dry mouth, hair loss, taste, anxiety, weight, flatulence, fecal incontinence, sore skin, embarrassment, stoma care problems, sexual interest for men, sexual interest for women, impotence, dyspareunia). There are 11 items allocated for specific sub-populations, including males, females, and stoma patients. Scores of the QLQ-CR29 can be linearly transformed to provide a score from 0 to 100, with higher scores representing higher levels of functioning on the functional scales, greater degrees of symptomatology on the symptom scales and improved QOL on the global QOL scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of acute adverse events as measured by CTCAE v 5.0</measure>
    <time_frame>From start of treatment through 3 months after completion of radiation therapy (estimated to be 3 months and 1 week)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of late adverse events as measured by CTCAE v 5.0</measure>
    <time_frame>From 3 month post-completion of radiation therapy to 12 months post-completion of radiation therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Recurrent Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Level 1: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-Radiotherapy will consist of five fractions, delivered once daily, with pencil beam scanning proton beam therapy using the defined dose in dose level 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-Radiotherapy will consist of five fractions, delivered once daily, with pencil beam scanning proton beam therapy using the defined dose in dose level 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-Radiotherapy will consist of five fractions, delivered once daily, with pencil beam scanning proton beam therapy using the defined dose in dose level 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy</intervention_name>
    <description>When feasible it is strongly recommended that radiotherapy begin on a Monday</description>
    <arm_group_label>Dose Level 1: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)</arm_group_label>
    <arm_group_label>Dose Level 2: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)</arm_group_label>
    <arm_group_label>Dose Level 3: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)</arm_group_label>
    <other_name>IMPT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine</intervention_name>
    <description>-The device that will administer the IMPT</description>
    <arm_group_label>Dose Level 1: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)</arm_group_label>
    <arm_group_label>Dose Level 2: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)</arm_group_label>
    <arm_group_label>Dose Level 3: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of biopsy-proven adenocarcinoma of the rectum, anus or rectosigmoid junction&#xD;
             of any stage now with recurrent disease in the pelvis&#xD;
&#xD;
          -  One prior course of radiation therapy to the pelvis for rectal cancer&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Women of childbearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control, abstinence) prior to study entry and for&#xD;
             the duration of study participation. Should a woman become pregnant or suspect she is&#xD;
             pregnant while participating in this study, she must inform her treating physician&#xD;
             immediately.&#xD;
&#xD;
          -  Able to understand and willing to sign an IRB-approved written informed consent&#xD;
             document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with pre-existing radiosensitizing conditions, such as connective tissue&#xD;
             disorders (i.e. lupus, scleroderma) and genetic mutations (i.e. ataxia-telangiectasia)&#xD;
&#xD;
          -  A history of other malignancy with the exception of malignancies for which all&#xD;
             treatment was completed at least 2 years before registration and the patient has no&#xD;
             evidence of disease, basal cell or squamous cell carcinoma of the skin that were&#xD;
             treated with local resection only, or carcinoma in situ of the cervix. Patients with&#xD;
             history of prostate cancer treated without radiotherapy and no evidence of disease are&#xD;
             eligible&#xD;
&#xD;
          -  More than one prior course of radiation to the pelvis for rectal cancer&#xD;
&#xD;
          -  Prior radiation to the pelvis for disease other than rectal cancer&#xD;
&#xD;
          -  Current treatment with any investigational agents.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, or unstable angina pectoris&#xD;
&#xD;
          -  Pregnant and/or breastfeeding. Women of childbearing potential must have a negative&#xD;
             urine or serum pregnancy test within 14 days of study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahed N Badiyan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shahed N Badiyan, M.D.</last_name>
    <phone>314-273-2931</phone>
    <email>sbadiyan@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shahed N Badiyan, M.D.</last_name>
      <phone>314-273-2931</phone>
      <email>sbadiyan@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Shahed N Badiyan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Re-I Chin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyun Kim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lauren Henke, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carl DeSelm, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yi Huang, M.S.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

